Skip to main content
. 2020 Mar 12;16:1744806920911543. doi: 10.1177/1744806920911543

Figure 1.

Figure 1.

Activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in central amygdala increases basal pain response. Basal pain thresholds measured by the tail–flick test before and after bilateral microinjection (arrows) of saline or AMPA (a, 0.1 μg in 0.5 μl each side), or the AMPA receptor antagonist cyanquixaline (6-cyano-7-nitroquinoxaline-2,3-dione (CNQX)) (b, 1.5 μg in 0.5 μl each side) into the central nucleus of amygdala. N = 6 rats in each group. *p <0.05. **p <0.01 (two-way analysis of variance with Bonferroni post hoc analysis).